Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | XIAP | P98170 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14170085 | 0.86 | ADRA2A (0.37) | ADRA2AHTR2A | |
| SCHEMBL14170089 | 0.79 | ADRA2A (0.42) | ALDH1A1SIGMAR1ADRA2AHTR2A | |
| SCHEMBL14169947 | 0.78 | SLC6A2 (0.37) | ALDH1A1SIGMAR1SMN1; SMN2GAAADRA2A | |
| SCHEMBL14170143 | 0.75 | ADRA2A (0.37) | ADRA2AHTR2A | |
| SCHEMBL14169899 | 0.74 | FNTA (0.50) | — | |
| SCHEMBL14170083 | 0.73 | KCNH2 (0.35) | ALDH1A1ADRA2AHTR2A | |
| SCHEMBL14172003 | 0.72 | ACE (0.52) | ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL14170253 | 0.71 | CACNA1G (0.43) | ALDH1A1SIGMAR1SMN1; SMN2ADRA2AHTR2A | |
| SCHEMBL14170087 | 0.69 | CYP3A4 (0.38) | ADRA2AHTR2A | |
| SCHEMBL8276173 | 0.68 | MEN1 (0.53) | ALDH1A1SMN1; SMN2XIAPADRA2AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390801-B2 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds | ATHENA NEUROSCIENCES, INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390801-B2 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds | ATHENA NEUROSCIENCES, INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-20070203108-A1 | Alzheimer's disease; 5-{N'-(4-thianaphthenacetyl)-L-alaninyl}-amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one | THORSETT EUGENE D | 2007-08-30 | — | — | US | disclosed |
| US-20070203108-A1 | Alzheimer's disease; 5-{N'-(4-thianaphthenacetyl)-L-alaninyl}-amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one | THORSETT EUGENE D | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203108-A1 | Alzheimer's disease; 5-{N'-(4-thianaphthenacetyl)-L-alaninyl}-amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one | APP, BACE1, PSEN1 | ALDH1A1 2775/4885SIGMAR1 4685/4885TMEM97 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.